GYRE THERAPEUTICS, INC. 8-K

What Happened

• Gyre Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 via a press release dated May 7, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K filed on May 7, 2026. The filing is signed by CEO Ying Luo.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Press release provided as Exhibit 99.1 to the Form 8-K.
• Report signed by Ying Luo, Chief Executive Officer and President.

Why It Matters

• This 8-K furnishes Gyre’s quarterly results and related information to investors; the press release is the primary source for revenue, earnings, and other operational metrics for Q1 2026.
• Retail investors should review Exhibit 99.1 (the press release) for the specific figures and any business updates, and monitor subsequent filings (e.g., Quarterly Report on Form 10-Q) for full financial statements and additional disclosures.